PVI
RETA

Pura Vida Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Pura Vida Investments’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-55,596
Closed -$1.4M – 259
2022
Q3 		$1.4M Buy
+55,596
New +$1.54M 0.08% 149

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Pura Vida Investments's RETA Position: Q4 2022 in Review

Pura Vida Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 55,596 shares — an estimated $1.4M sold.

Pura Vida Investments first reported a position in RETA in Q3 2022 and held it in 1 quarter. The position peaked at $1.4M in Q3 2022. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

  • Pura Vida Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • Pura Vida Investments sold 55,596 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $1.4M.
  • Pura Vida Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2022 and held it in 1 quarter.
  • Pura Vida Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.4M in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.